Online ISSN: 2515-8260

Keywords : GIST

Histopathological Study of Gastrointestinal Stromal Tumors

Maulik kumar P. Vora, Abhishek Raval, Manan Jadav, Ritesh Gohil, Karansinh F. Vala

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 7, Pages 3761-3767

Background: Gatrointestinal stromal tumor (GIST), now the most common mesenchymal tumor of the gastrointestinal tract(GIT), has been frequently studied.
Objectives: Our aim was to study histopathology, demographic profile, histopathological grading, IHC property and behavior of  Gastro intestinal stromal tumor(GIST)
Material & Methods: Retrospectively 50 cases were selected& studied from the department of histopathology of tertiary care hospital,  Ahmedabad, India during  june 2010 to june 2013
Results: 50 cases were studied in our study. Most common site was stomach(40%)followed by jejunum(18%), rectum(16%)& ileum(12%). Most common age group was 51-60 years. Most common presenting symptoms  was abdominal pain (70%)  Seventy  percent of  Gastrointestinal stromal tumor were positive for CD 117(KIT). Histologically majority of them had a pure spindle cell morphology. Eight patients (21%)  had  recurrent /residual  mass of presentation.
Conclusion: In our study large number of  Gastro intestinal stromal tumor were present in the stomach. Most common age group was 51-60 years. Majority of  them  were of pure spindle cell morphology. Molecular studies and larger numbers of cases are required for meaningful conclusion to be drawn.

Clinico pathological features and outcomes of gist: A five year retrospective data from a tertiary cancer care centre in south India

Naveen Ravel, Teena Rajan, Sathiyamoorthy P.N., Arun Ramanan, Chodavarapu Dheeraj, Meena K, Pothala Vijayalakshmi

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 10728-10732

Background and aims: Gastrointestinal stromal tumours (GISTs) are the most common
mesenchymal neoplasms that arise in the gastrointestinal tract.They constitute about
0.1-3% of all GI tumours. Annual incidence is 1.2 per 105 individuals. Surgery remains
the main stay of treatment. The use of adjuvant TKI Imatinib mesylate for 3 years
reduce the frequency of disease recurrencefollowing complete resection.Five year
survival for all stages combined is upto 83%.Here we present a five year retrospective
data on the clinicopathological features and outcomes of GIST from a tertiary cancer
care centre in south India.
Methods: This retrospective study was conducted in a tertiary cancer care centre in
South India.Medical records of all consecutive patients with biopsy and IHC
(Immunohistochemistry) proven GIST cases from January 2017 to December 2021 were
collected, reviewed and analysed .
Results: 38 cases of biopsy and IHC proven GISTs were analysed. Median age was 54
years. 20 were males and 18 were females .The most common primary site was
stomach(45%) followed by small intestine(39%).Majority of the patients were stage III
at presentation (53%). 26 of cases were metastatic at presentation. Primary surgery was
offered in 55% of the patients.68% of the patients received adjuvant treatment with
Imatinib. 83 % of patients (10/12) who completed 3 years of adjuvant treatment
remained disease free and 82% of all patients (31/38) are alive at the time of analysis.
There was no progression in stage IV GISTs treated with Imatinib. 31% of patients
developed GI toxicity with imatinib. Recurrence was seen in only 4 patients (14%) who
received adjuvant TKI (Tyrosine kinase inhibitors). Common sites of recurrence was
liver (50%) and omental and peritoneal secondaries.(50%).Progression on second line
therapy with Sunitinib was seen only in one case of recurrent GIST.
Conclusion: Adjuvant Imatinib is efficacious and is well tolerated by our
population.83% of the patients who completed adjuvant therapy are disease free at 2
years.5 year survival rate is about 82%.There is no grade 3 or 4 toxicity with Imatinib.